Is Nephros, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics.
Despite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market.